Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis.
Lin S, Wang L, Han C, Dai Y, Li C, Liu Y, Zhang B, Huang N, Zhang A, Zhang T, Wang Y, Xie J, Tang H, Cheng Y, Yao H, Lou M, Xue L, Wu ZB.
Lin S, et al. Among authors: wu zb.
Neuro Oncol. 2024 Nov 4;26(11):2010-2026. doi: 10.1093/neuonc/noae130.
Neuro Oncol. 2024.
PMID: 38989697